Vetter has reached several milestones in the development of its next-generation tamper-evident syringe closure system, V-OVS® next, moving the product closer to commercial launch in 2027. The Germany-based contract development and manufacturing organization said the design of the updated closure has been finalized and preparations for industrialization are underway.
The company developed V-OVS® next based on market feedback to improve handling, functionality, and design across a range of syringe formats. The system targets applications including ophthalmology, aesthetics, biologics, and diluents.
Vetter said it has completed additional usability and performance testing, including two Human Factors studies and a functional assessment. The results, according to the company, confirmed that the new design offers improved safety, user experience, and structural performance compared with the original V-OVS® system.
As part of commercial readiness efforts, Vetter has begun providing syringe suppliers with non-finalized housing unit materials for further testing and integration. The final product will be compatible with existing V-OVS® materials, allowing customers to adopt the new design without modifying contact components.
Vetter plans to offer both the original and updated closure systems following commercialization to accommodate a range of product lifecycle needs.